Table 2.

Kaplan Meier univariate analysis of the Specific Survival (SS) and Metastasis Free Survival (MFS) of 74 inflammatory breast carcinomas

	N of patients(%)	5-year SS	p SS	5-year MFS	p MFS
ALDH1
negative	37 (70%)	53.69 [36.7–78.6]	0.0337	48.54 [31.2–75.4]	0.0152
positive	16 (30%)	25.24 [10.2–62.7]		21.09 [7.81–57]
Age (years)
<45	22 (30%)	43.87 [25.6–75.2]	NS	28.72 [13.2–62.5]	NS
≥45	52 (70%)	43.43 [30.3–62.2]		44.27 [30.4–64.4]
Axillary lymph node status
negative	5 (7%)	NR	NS	NR	NS
positive	63 (93%)	40.33 [28.5–57.2]		35.7 [23.9–53.2]
BCL2
negative	35 (66%)	32.02 [17.7–58]	0.00929	36.05 [20.4–63.7]	0.064
positive	18 (34%)	86.15 [70–100]		63.03 [41–97]
CD44+/CD24− phenotype
absent	23 (37%)	41.8 [26.8–65.2]	NS	42.4 [25.1–71.8]	NS
present	39 (63%)	41 [26.3–63.7]		44.5 [27.4–72.13]
E-Cadherin
negative	24 (51%)	50.29 [27.9–90.6]	NS	32.37 [12.5–84]	NS
positive	23 (49%)	41.09 [24.9–67.8]		41.67 [24.6–70.6]
ER
negative	22 (51%)	11.94 [2.15–66.3]	0.00909	24.24 [8.74–67.3]	0.00454
positive	21 (49%)	49.26 [28.3–85.7]		35.38 [14.9–83.8]
ERBB2
0–1	26 (55%)	59.42 [40.8–86.6]	NS	38.85 [19.9–75.8]	NS
02-Mar	21 (45%)	47.12 [27.5–80.8]		58.5 [39.9–85.7]
Ki67
≤20	20 (51%)	22.79 [8.77–59.3]	0.0797	12.57 [2.22–71.1]	NS
>20	19 (49%)	41.22 [20.5–82.7]		43.2 [21.1–88.6]
MUC1
negative	24 (50%)	68.66 [50–94.3]	NS	53.8 [33.4–86.6]	NS
positive	24 (50%)	30.41 [14.5–63.8]		29.54 [12.9–67.7]
PR
negative	24 (57%)	15 [4.47–50.3]	0.00377	9.549 [1.6–57.1]	0.00148
positive	18 (43%)	52.88 [29.5–94.9]		49.33 [23.3–100]
SBR grade
I	3 (4%)	100 [100–100]		50 [12.5–100]
II	16 (22%)	41.27 [20.1–84.9]	NS	31.25 [11.8–83]	NS
III	54 (74%)	40.01 [27.7–57.8]		42.53 [29.5–61.3]